Neurogene Inc.
NASDAQ:NGNE · NASDAQ Global Market
+$0.76 today
Vol 0.28M · Avg 0.16M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $124.2M |
| Short-term Investments | $119.0M |
| Other Current | $3.6M |
| Total Current Assets | $246.7M |
| PP&E (Net) | $15.0M |
| Other Non-current | $1.4M |
| Total Non-current Assets | $16.4M |
| Total Assets | $263.1M |
Analysis
Selected assets total $263.1M for Latest. The largest visible component is Cash & Equivalents at $124.2M, about 47.2% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $103.8M -24.0% | $136.6M -7.8% | $148.2M +80.7% | $82.0M +16.3% | $70.5M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $165.2M -6.1% | $175.8M +259.2% | $48.9M | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $0 -100.0% | $648.0K +8.0% | $600.0K | $0 -100.0% | $790.0K | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 -100.0% | $1.9M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $2.8M +181.0% | $981.0K -10.4% | $1.1M -32.4% | $1.6M +234.8% | -$1.2M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $271.8M -14.0% | $315.9M +57.7% | $200.3M +136.5% | $84.7M +14.6% | $74.0M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $15.5M -16.4% | $18.5M -11.7% | $21.0M -14.6% | $24.5M -10.8% | $27.5M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 -100.0% | $128.0K | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 -100.0% | $878.0K | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $1.4M +4.4% | $1.3M +3.3% | $1.3M | $0 +100.0% | -$1.0M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $16.8M -15.0% | $19.8M -10.9% | $22.2M -9.5% | $24.5M -10.8% | $27.5M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $288.6M -14.0% | $335.7M +50.8% | $222.6M +103.7% | $109.3M +7.7% | $101.5M | $13.3B | $11.9B | $10.6B |
| Account Payables | $2.0M +46.2% | $1.3M -48.5% | $2.6M +315.4% | $625.0K -88.9% | $5.6M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $3.1M +2.2% | $3.0M | $0 | $0 -100.0% | $1.2M | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $6.3M +341.2% | $1.4M -78.6% | $6.7M +3917.4% | $167.0K +26.5% | $132.0K | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $16.4M +8.3% | $15.2M -34.0% | $23.0M +245.4% | $6.7M -38.7% | $10.9M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $6.8M | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $479.0K -37.7% | $769.0K +278.8% | $203.0K | $0 -100.0% | $177.9M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $7.3M -28.4% | $10.2M -24.9% | $13.6M +240.5% | $4.0M -97.8% | $182.5M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $23.7M -6.5% | $25.4M -30.6% | $36.5M +243.6% | $10.6M -94.5% | $193.4M | $14.7B | $3.7B | $9.6B |
| Common Stock | $0 | $0 | $0 | $0 -100.0% | $1.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$352.6M -34.4% | -$262.3M -40.2% | -$187.2M -24.1% | -$150.8M -57.7% | -$95.6M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $0 | $0 | $0 | $0 | $0 | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $264.9M -14.7% | $310.4M +66.8% | $186.0M +88.6% | $98.6M +207.3% | -$91.9M | $9.1B | $7.7B | $3.3B |
| Total Debt | $9.9M -20.4% | $12.4M -23.5% | $16.3M +246.7% | $4.7M -27.1% | $6.4M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$94.0M +24.3% | -$124.2M +5.9% | -$132.0M -70.6% | -$77.3M -20.6% | -$64.1M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Alumis Inc. Common Stock
NASDAQ:ALMS
$2.83B
Solid Biosciences Inc.
NASDAQ:SLDB
$590.56M
Ocugen, Inc.
NASDAQ:OCGN
$429.92M
PureTech Health plc
NASDAQ:PRTC
$421.39M
Autolus Therapeutics plc
NASDAQ:AUTL
$407.20M
Benitec Biopharma Inc.
NASDAQ:BNTC
$314.96M
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
$304.14M
Quantum-Si incorporated
NASDAQ:QSI
$190.92M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$189.66M
ADC Therapeutics S.A.
NYSE:ADCT
$138.00M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does NGNE have?
Neurogene Inc. (NGNE) reported $103.84M in cash and equivalents in fiscal 2025.
How much debt does NGNE carry?
Neurogene Inc. (NGNE) reported $9.89M of total debt, with net debt of -$93,954,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.